Michael Klemm, CEO, and Matthijs van Waveren, marketing coordinator for the OpenMP ARB, along with Jim Cownie, principal engineer, Intel Corporation (UK), consider the development of OpenMP over the last 20 years
Gemma Church explains the background behind explosive growth in the simulation and modelling of low- and high-frequency electronics
Robert Roe talks to Southampton University’s Oz Parchment about the decision-making behind the latest HPC system at the University
With innovation in cooling technology increasingly more important to ensure energy, performance and cost efficiency of HPC, Keely Portway speaks to experts to find out what is driving the latest innovations
Robert Roe discusses the potential for software-defined storage with Excelero’s Josh Goldenhar
Robert Roe looks at recent developments in processor and accelerator technology
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
